title: Into the Clinic With Nivolumab and Pembrolizumab.
authors.affiliation: Division of Hematology/Oncology, Columbia University Medical Center, New York, New York, USA.
authors.forename: Catherine A
authors.initials: CA
authors.lastname: Shu
authors.affiliation: Division of Hematology/Oncology, Columbia University Medical Center, New York, New York, USA nar2144@cumc.columbia.edu.
authors.forename: Naiyer A
authors.initials: NA
authors.lastname: Rizvi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000096:biosynthesis; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D000077594:Nivolumab; C582435:pembrolizumab